Analysis of Factors Influencing the Quality of Bowel Preparation Before Colonoscopy in IBD Patients

Step 1: During the issuance of a colonoscopy order, outpatient/ward physicians conduct preliminary screening and introduction to potential participants. Alternatively, recruitment may take place during follow-up in the recovery room or ward after the patient completes the colonoscopy (must be within 7 days post-procedure to reduce recall bias). Provide detailed explanations of the study content, risks, and benefits to potential subjects.

Step 2: Ensure that the patient fully understands the study, and then proceed to sign the "Informed Consent Form."

Step 3: Patients complete the "Questionnaire on Factors Influencing Bowel Preparation in IBD Patients." The questionnaire covers two main aspects: First, potential risk factors that may affect the quality of bowel preparation, including BMI, history of abdominal surgery, history of diabetes, history of diarrhea or constipation, stool characteristics, etc. Second, the specific bowel preparation protocol, including pre-colonoscopy diet, type of bowel cleansing agent used, dosage, interval between completion of medication and start of colonoscopy (waiting time), timing of medication intake, etc. Finally, the researcher records the bowel preparation quality score and colonoscopy results, including Boston Bowel Preparation Scale scores for each intestinal segment, colonoscopic diagnosis, endoscopic disease activity scores, etc.

Inclusion criteria

• Patients aged 18 years or older, of any gender, scheduled for colonoscopy;
• Patients diagnosed with Inflammatory Bowel Disease (IBD) according to the 2023 edition of the Guidelines for the Diagnosis and Treatment of Inflammatory Bowel Disease;
• Voluntary participation in this study and provision of signed informed consent.

Exclusion criteria

• History of acute myocardial infarction (within the past 6 months), severe cardiac, hepatic, or renal insufficiency, or psychiatric disorders;
• Current use of anticoagulants (e.g., aspirin, warfarin) or presence of coagulation disorders;
• Pregnant or lactating women;
• Acute intestinal infection within the past 2 weeks;
• History of colorectal tumors, familial adenomatous polyposis, or Peutz-Jeghers syndrome;
• History of intestinal obstruction, perforation, stenosis, or any other condition preventing completion of the examination;
• Severe hearing impairment, cognitive dysfunction, or inability to cooperate with the survey;
• Individuals already enrolled in this study who schedule a repeat colonoscopy;
• Currently participating in another clinical observational trial or having participated in any other clinical trial within the past 60 days;
• Refusal to sign the written informed consent form.